TherageniX
NLC Health Ventures is a world-leading healthtech venture builder and early-stage investor dedicated to transforming patients' lives by bridging scientific discoveries with market-ready solutions. They focus on finding, building, and scaling innovative healthcare technologies across various therapeutic areas, with a mission to create a healthier future through impactful ventures and collaborations. Their expertise spans cardiovascular, orthopedics & spine, therapeutics, general healthtech, neonatal, respiratory technologies, enterprise software for hospitals, and more, enabling them to develop ventures that address critical healthcare challenges.
Industries
Nr. of Employees
small (1-50)
TherageniX
AHTC Building, Paasheuvelweg 25-D5, 1105 BP Amsterdam, The Netherlands
Products
Secure privacy-preserving genomic and clinical analytics platform
Platform for secure, real-time analysis of genomic, clinical and phenotypic data using AI and privacy-preserving encryption to support rare disease interpretation.
Oral capsule system for macromolecule delivery
Capsule-based delivery system designed to administer large-molecule therapeutics in the gastrointestinal tract to enable oral delivery of biologics.
Point-of-care rapid biomolecule diagnostic platform
Platform for rapid, sensitive measurement of biomolecules at the point of care intended to substitute laboratory assay workflows.
Intraoperative gene therapy for bone graft augmentation
Application of gene-based regenerative therapies to autologous bone grafts during surgery to enhance bone repair.
Patient-specific 3D surgical planning and printed guides
Patient-specific 3D surgical planning, printed guides and specialized tools for implant revision surgery and surgical assistance.
Rapid host-response sepsis diagnostic test
Rapid assay combining host gene expression and metabolic markers with machine-learning interpretation to enable fast sepsis detection from small blood samples.
Secure privacy-preserving genomic and clinical analytics platform
Platform for secure, real-time analysis of genomic, clinical and phenotypic data using AI and privacy-preserving encryption to support rare disease interpretation.
Oral capsule system for macromolecule delivery
Capsule-based delivery system designed to administer large-molecule therapeutics in the gastrointestinal tract to enable oral delivery of biologics.
Point-of-care rapid biomolecule diagnostic platform
Platform for rapid, sensitive measurement of biomolecules at the point of care intended to substitute laboratory assay workflows.
Intraoperative gene therapy for bone graft augmentation
Application of gene-based regenerative therapies to autologous bone grafts during surgery to enhance bone repair.
Patient-specific 3D surgical planning and printed guides
Patient-specific 3D surgical planning, printed guides and specialized tools for implant revision surgery and surgical assistance.
Rapid host-response sepsis diagnostic test
Rapid assay combining host gene expression and metabolic markers with machine-learning interpretation to enable fast sepsis detection from small blood samples.
Services
End-to-end incubation for early-stage healthcare ventures including technical maturation, team formation and operational support.
Management of investment vehicles that provide seed and follow-on capital to portfolio ventures, with investor relations and structured capital deployment.
Design and execution of collaborative pilots and partnership agreements to test, validate and integrate technologies within corporate and clinical environments.
Scientific and commercial due diligence, expert review and development planning to define milestones and de-risk early-stage programs.
Assessment and reporting of venture- and fund-level impact using standardized metrics and disclosure practices aligned with sustainable finance frameworks.
Centralized operational infrastructure and shared resources to support multiple ventures, including program management, legal, finance and go-to-market activities.
End-to-end incubation for early-stage healthcare ventures including technical maturation, team formation and operational support.
Management of investment vehicles that provide seed and follow-on capital to portfolio ventures, with investor relations and structured capital deployment.
Design and execution of collaborative pilots and partnership agreements to test, validate and integrate technologies within corporate and clinical environments.
Scientific and commercial due diligence, expert review and development planning to define milestones and de-risk early-stage programs.
Assessment and reporting of venture- and fund-level impact using standardized metrics and disclosure practices aligned with sustainable finance frameworks.
Centralized operational infrastructure and shared resources to support multiple ventures, including program management, legal, finance and go-to-market activities.
Expertise Areas
- Venture building and early-stage investment
- Fund formation and fund management
- Biotechnology and therapeutic development
- Medical devices and orthopedic implant technologies
Key Technologies
- AAV gene therapy vectors
- microRNA delivery systems
- Small-molecule drug discovery
- Oral capsule macromolecule delivery systems
News & Updates
NLC & HMG launch the Global Open Challenge!
NLC Health Ventures and HMG are announcing partnership to accelerate global health tech innovations
NLC completes first close of €100 million health impact fund
NLC was recognized as the most active early-stage investor in healthcare across Europe by Financial Times’ Sifted.
NLC's venture Altach secured €1.2 million to develop treatments for cartilage injuries, aiming to improve outcomes and reduce surgeries.
The NLC Health Impact Fund invested GBP 210,000 in Amotio, a venture developing non-invasive solutions for revision joint surgeries.
NLC & HMG launch the Global Open Challenge!
NLC Health Ventures and HMG are announcing partnership to accelerate global health tech innovations
NLC completes first close of €100 million health impact fund
NLC was recognized as the most active early-stage investor in healthcare across Europe by Financial Times’ Sifted.
NLC's venture Altach secured €1.2 million to develop treatments for cartilage injuries, aiming to improve outcomes and reduce surgeries.
The NLC Health Impact Fund invested GBP 210,000 in Amotio, a venture developing non-invasive solutions for revision joint surgeries.